Legend shares suffer on CEO 'residential surveillance' drama

21 September 2020

Shares in Legend Biotech (Nasdaq: LEGN) fell by nearly 16% in the first four hours of trading on Monday.

This was not due to results on a drug candidate, but rather on Legend’s appointment of chief financial officer Ying Huang as interim chief executive, effective immediately, due to a drama involving the previous boss Fangliang Zhang and other employees.

A statement from the company said that on Friday it learned that China’s Customs Anti-Smuggling Department inspected places of business of GenScript Biotech Corporation, Legend Biotech’s parent majority shareholder, and certain of its subsidiaries, including Legend’s office in Nanjing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK